Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Camurus AB (CAMRF)
OTHER OTC:CAMRF
Holding CAMRF?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.16Last Year’s EPS
-$0.02Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -5.79%
|Next Earnings Date:Feb 13, 2025
Earnings Call Sentiment|Positive
The earnings call presented strong financial performance and growth in key product sales, along with a solid cash position. However, challenges such as the FDA's CRL and increased operating expenses were noted. The positive aspects of growth and profitability were more pronounced, leading to an optimistic outlook.Company Guidance
During the Q3 2024 earnings call for Camurus (CAMX.ST), the company provided an optimistic update on its financial and operational performance. Revenue in the third quarter increased by 38% year-on-year to SEK 480 million, with an impressive profit before tax surge of 125% to SEK 165 million. The quarter also saw Buvidal sales climb by 22% to SEK 421 million, while Brixadi net sales in the U.S. rose by 39% quarter-on-quarter, contributing SEK 58 million in royalties. The company's gross margin reached 93%, and its cash position improved to SEK 2.75 billion, maintaining a debt-free status. The company revised its full-year 2024 outlook upwards, anticipating total revenue between SEK 1,810 million and SEK 1,880 million, and a profit before taxes in the range of SEK 450 million to SEK 510 million. R&D advancements were highlighted by positive Phase III results and ongoing regulatory progress, despite a CRL from the FDA due to a cGMP inspection issue. Camurus remains focused on meeting its 2027 vision, buoyed by strong year-to-date performance and promising Q4 expectations.Record Revenue Growth
Camurus achieved a revenue growth of 38% year-on-year, reaching SEK 480 million, excluding a one-time revenue in 2023.
Increased Profitability
Profit before tax increased by 125% to SEK 165 million in Q3, excluding the one-time milestone.
Strong Cash Position
Cash position increased to SEK 2.75 billion, with no debt.
Buvidal and Brixadi Sales Growth
Buvidal sales grew by 22% year-on-year to SEK 421 million, and Brixadi net sales increased by 39% quarter-on-quarter, resulting in a SEK 58 million royalty contribution.
Positive R&D Advancements
Advanced R&D pipeline with positive Phase III results from the ACROINNOVA 2 study and progress in U.S. NDA labeling.
---
CAMRF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CAMRF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $54.10 | $56.80 | +4.99% |
| Jul 16, 2024 | $61.55 | $62.60 | +1.71% |
| May 08, 2024 | $45.00 | $48.88 | +8.62% |
| Feb 15, 2024 | $50.16 | $42.36 | -15.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Camurus AB (CAMRF) report earnings?
Camurus AB (CAMRF) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Camurus AB (CAMRF) earnings time?
Camurus AB (CAMRF) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CAMRF EPS forecast?
CAMRF EPS forecast for the fiscal quarter 2024 (Q4) is $0.16.
---